Impact of glycosylation on the effect of cytokines. A special focus on oncology.
Impact of glycosylation on the effect of cytokines. A special focus on oncology.
复制标题
糖基化对细胞因子作用的影响。
作者：
Anne;N. Magné;X. Pivot;G. Milano
细胞因子的临床应用主要局限于癌症治疗领域。细胞因子制备的工业程序可能会也可能不会影响几种细胞因子的糖基化状态。细胞因子的糖基化可能对其生物学功能的实现至关重要，包括它们的生物稳定性、与特定受体的相互作用以及它们的药代动力学行为。因此，本综述的目的是描述和讨论细胞因子糖基化的作用，基于实验数据，并从肿瘤学的临床角度。糖基化对细胞因子活性的影响没有普遍规律。在与糖基化状态相关的不同细胞因子中，G-CSF的数据足以将实验结果转化为临床证据。对于这种细胞因子，糖基化具有稳定性和生物活性两方面的优势。虽然在重量相等的情况下，糖基化形式比非糖基化形式具有更大的生物活性，但临床研究表明，当糖基化和非糖基化的G-CSF以生物等效剂量处方时，其疗效仍然相同。
The clinical use of cytokines is largely confined to the field of cancer treatment. Industrial procedures for the preparation of cytokines may or may not affect the glycosylation status of several cytokines. The glycosylation of cytokines may be of importance for the accomplishment of their biological functions, including their biological stability, their interaction with specific receptors and their pharmacokinetic behavior. The purpose of this review is thus to describe and discuss the role of cytokine glycosylation, based on experimental data, and with the clinical perspective on oncology. There is no general rule governing the effects induced by the presence of glycosylation on cytokine activity. Among different cytokines concerned by glycosylation status, data concerning G-CSF are sufficient to translate experimental findings into clinical evidence. For this cytokine, glycosylation confers advantages for both stability and biological activity. Although at weight equivalence, the glycosylated form confers greater biological activity than the non-glycosylated form, clinical studies have demonstrated that efficacy remains the same when glycosylated and non-glycosylated G-CSF are prescribed at bioequivalent doses.